

17 March 2026

Cleansing Notice - Placement

OncoSil Medical Limited ACN 113 824 141 (ASX: OSL) (the **Company**), announced today that it has issued 4,100,470 fully paid ordinary shares in the Company at an issue price of \$0.68 per share to sophisticated and institutional investors (**Placement Shares**).

The Company gives this cleansing notice (**Notice**) under section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**). The Placement Shares were issued without disclosure to institutional and sophisticated investors under Part 6D.2 of the Corporations Act.

As at the date of this Notice the Company advises that:

- (a) the Company has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) sections 674 and 674A of the Corporations Act; and
- (b) there is no information that is "excluded information" within the meaning of sections 708A(7) and (8) of the Corporations Act.

The release of this announcement was authorised by the Board of the Company.

Yours faithfully

Mr. Tim Luscombe
Company Secretary
OncoSil Medical Limited

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Tim Luscombe Company Secretary E: tim.luscombe@bio101.com T: +61 429 707 079	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338
--	---	---

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>